ImmuPharma plc (LON:IMM – Get Free Report) shares shot up 24.4% during trading on Tuesday . The stock traded as high as GBX 7.30 ($0.09) and last traded at GBX 6.84 ($0.09). 59,930,031 shares were traded during trading, an increase of 156% from the average session volume of 23,372,244 shares. The stock had previously closed at GBX 5.50 ($0.07).
ImmuPharma Stock Performance
The stock has a market capitalization of £24.65 million, a price-to-earnings ratio of -592.00 and a beta of 1.53. The company has a fifty day simple moving average of GBX 1.83 and a 200 day simple moving average of GBX 1.75.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- What is the MACD Indicator and How to Use it in Your Trading
- 3 Consumer Stocks Call Option Traders Are Betting Big On
- How to Read Stock Charts for Beginners
- Duolingo: An Unexpected Benefactor From the TikTok Ban
- About the Markup Calculator
- Trump Index: 6 Companies Linked to Trump’s Cabinet Worth Watching
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
